GlassScriptPhysician profile
Jacquelyn Sturm
NPI 1134311087
$9,013.12
in general payments reported to CMS, 2019-2025
29 companies · $3,082 in 2025
The $3,082 reported for 2025 was more than what 77% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2020: $475 · 2021: $1,427 · 2022: $1,049 · 2023: $651 · 2024: $1,473 · 2025: $3,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,617 · Consulting Fee: $1,470 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,616.89 |
| Consulting Fee | $1,470.27 |
| Education | $118.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,195.42 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,421.81 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $1,330.89 | 2020-2025 | Cuvitru, Hyqvia, Eohilia |
| Glaxosmithkline, LLC. | $789.40 | 2019-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $650.33 | 2019-2025 | Dupixent |
| Csl Behring | $500.96 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Optinose US, INC. | $359.39 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $252.78 | 2019-2025 | |
| Amgen INC. | $202.72 | 2022-2025 | Tezspire |
| Pfizer INC. | $187.96 | 2019-2025 | |
| Genentech USA, INC. | $172.85 | 2019-2023 | Xolair |
| Kaleo, INC. | $132.61 | 2019-2024 | Auvi-Q |
| Octapharma USA, INC. | $108.42 | 2022-2025 | Octagam Immune Globulin (Human) |
| Grifols USA, LLC | $94.81 | 2019-2024 | Xembify |
| Sanofi-Aventis U.S. LLC | $84.99 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $72.50 | 2021-2023 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $61.07 | 2019-2022 | |
| Ionis Pharmaceuticals, INC. | $55.26 | 2025 | Donidalorsen, Dawnzera |
| Abbvie INC. | $54.71 | 2024 | |
| Azurity Pharmaceuticals, INC. | $53.64 | 2025 | Alvesco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.62 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $41.00 | 2025 | Neffy |
| Organon LLC | $25.33 | 2025 | |
| Adma Biomanufacturing LLC | $24.27 | 2025 | |
| Impel Pharmaceuticals INC. | $22.02 | 2023 | Trudhesa |
| Merck Sharp & Dohme LLC | $19.05 | 2021 | |
| Phadia US INC. | $17.50 | 2021 | |
| Paratek Pharmaceuticals, INC. | $15.52 | 2025 | Nuzyra, Xhance |
| Alk-Abello, INC | $13.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelyn Sturm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.